September 16th 2020
By Tony Hagen
A broader range of indications in rheumatology combined with a Canadian push for biosimilar acceptance bodes well for Merck's Brenzys product.
September 15th 2020
Courts have allowed biosimilar developers "safe harbor" against infringement suits, but there are limits, attorneys from Goodwin Proctor explain.
September 14th 2020
By Skylar Jeremias
With anti–tumor necrosis factor (TNF) therapy showing promise in treating coronavirus disease 2019 (COVID-19), authors called for these agents to have a higher priority in research.
September 11th 2020
In the effort to find treatments for coronavirus disease 2019 (COVID-19) and related conditions, Celltrion Healthcare’s monoclonal antibody has shown promise in a phase 1 trial.
September 5th 2020
By Sarfaraz K. Niazi, PhD
September 3rd 2020
Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
September 1st 2020
The Australia-based biosimilar company hopes to compete with blockbuster programmed death-1 (PD-1) inhibitor franchises owned by Merck and Bristol Myers Squibb.
A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).
August 31st 2020
By Deana Ferreri, PhD
Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.
August 24th 2020
From China to Taiwan, BeiGene and Bio-Thera Solutions hope to capture a large share of the bevacizumab biosimilar market.
